Family-Focused Study to Support Medication for Opioid Use Disorder
Family-focused Digital Intervention for MOUD Initiation and Retention
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Klaren Pe-Romashko, MS
- Email: kspe@wisc.edu
Study Contact Backup
- Name: Gina Landucci, BS
- Email: gina.landucci@wisc.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60187
- Northwestern University Feinberg School of Medicine
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53706
- University of Wisonsin-Madison
-
Contact:
- Klaren Pe-Romashko
- Email: kspe@wisc.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Be 18 years or older who meet the criteria for moderate or severe opioid use disorder (OUD) as determined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Referred to as the "Identified Patient" or IP.
- Be a parent, spouse or committed romantic partner, other family member, or friend, age 21 or older, of the individual with OUD. Referred to as "Concerned Significant Other" or CSO.
- Able to communicate fluently in English.
- Own a smartphone.
Exclusion Criteria:
- IP must not have been on MOUD in the last 2 weeks.
- CSO must not meet criteria for any severity of substance use disorder (SUD), except tobacco use.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: FamilyCHESS (Family Comprehensive Health Enhancement Support System)
Participant dyads will receive FamilyCHESS
|
Participants will have access to the FamilyCHESS system on their personal smartphone.
FamilyCHESS incorporates Invitation to Change (ITC), a combination of Community Reinforcement and Family Training (CRAFT), Acceptance and Commitment Therapy (ACT), and Motivational Interviewing (MI) training principles and components for a CSO (e.g., parent, spouse/romantic partner, adult child, other family member or friend) to encourage and support the patient to engage in treatment.
|
|
Active Comparator: Control
Participant dyads will receive standard of care treatment for MOUD
|
Participants will receive links to Substance Abuse and Mental Health Services Administration (SAMHSA) resources for MOUD
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Initiation of MOUD
Time Frame: 12 months
|
Number of days between study start date and MOUD initiation date.
|
12 months
|
|
Continuity on MOUD
Time Frame: 4, 8, and 12 months
|
Collected through self-report.
Percentage of days IPs in the intervention arm are on MOUD compared to control arm.
|
4, 8, and 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in IP Quality of Life
Time Frame: Baseline, 4, 8, and 12 months
|
Quality of life (QOL) is measured using the SF-12 Health Survey, which is a 12-item questionnaire.
It is scored on a variable Likert scale.
Scores range from 12 to 47 where higher scores indicate greater quality of life.
|
Baseline, 4, 8, and 12 months
|
|
Change in number of opioid overdoses
Time Frame: Baseline, 4, 8, and 12 months
|
IPs will self-report whether, and how many, overdoses they experienced in the previous 30 days.
An opioid overdose occurs when someone turns blue, has little or no breathing, or passes out and cannot be woken up without help after using opioids.
|
Baseline, 4, 8, and 12 months
|
|
Change in number of emergency room visits
Time Frame: Baseline to 12 months
|
Baseline to 12 months
|
|
|
Change in percentage of days of opioid use
Time Frame: Baseline, 4, 8, and 12 months
|
IPs will self-report the number of days they used any illegal/street drugs, abuse any prescription medications, or drink alcohol over the previous 30 days.
It will be reported as a percentage of overall days of use
|
Baseline, 4, 8, and 12 months
|
|
Change in McMaster Family Functioning Scale (FAD-GF)
Time Frame: Baseline, 4, 8, and 12 months
|
FAD-GF is a 12 item questionnaire using a 4-point Likert scale. 1 = strongly agree and 4 = strongly disagree.
Odd items are reverse scored.
Once the odd items have been reverse scored the participant's family functioning score is the sum of the 12 items, which ranges from 12-48, where higher scores indicate better family functioning.
|
Baseline, 4, 8, and 12 months
|
|
Change in CSO coping styles
Time Frame: Baseline, 4, 8, and 12 months
|
CSOs will complete a 30-item survey about coping strategies.
It is scored on a 3-point Likert scale where no = 0 and often = 3. Scores range from 0-90, where higher scores indicate better coping strategies.
|
Baseline, 4, 8, and 12 months
|
|
Change in CSO perceptions of social support
Time Frame: Baseline, 4, 8, and 12 months
|
Using the Alcohol, Drugs and the Family Support Scale, CSOs will rate their perception of social support.
The scale is a 25 item survey which uses a 3-point Likert scale where 0 = never and 3 = often (some items are reverse scored).
Scores range from 0-75.
Higher scores indicate greater sense of support.
|
Baseline, 4, 8, and 12 months
|
|
Change in CSO Quality of Life
Time Frame: Baseline, 4, 8, and 12 months
|
QOL is measured using the SF-12 Health Survey, which is a 12-item questionnaire.
It is scored on a variable Likert scale.
Scores range from 12 to 47 where higher scores indicate greater quality of life.
|
Baseline, 4, 8, and 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Todd Molfenter, PhD, University of Wisconsin, Madison
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Narcotic-Related Disorders
- Mental Disorders
- Neoplasms
- Immune System Diseases
- Neoplasms by Histologic Type
- Substance-Related Disorders
- Chemically-Induced Disorders
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Hemic and Lymphatic Diseases
- Opioid-Related Disorders
- Lymphoma, Follicular
- Health Services Administration
- Health Care Quality, Access, and Evaluation
- Quality of Health Care
- Quality Indicators, Health Care
- Standard of Care
Other Study ID Numbers
Other Study ID Numbers
- 2026-0264
- 1R61DA061326-01A1 (U.S. NIH Grant/Contract)
- UWMSN | COE | Industrial and S (Other Identifier: UW Madison)
- Protocol Version 2/16/26 (Other Identifier: UW Madison)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.